中国医药科学
中國醫藥科學
중국의약과학
CHINA MEDICINE AND PHARMACY
2014年
20期
173-175
,共3页
参芪扶正注射液%GP方案%非小细胞肺癌
參芪扶正註射液%GP方案%非小細胞肺癌
삼기부정주사액%GP방안%비소세포폐암
Shenqifuzheng%GP regimen%Non-small cell lung carcinoma
目的：通过对比参芪扶正联合GP方案与GP方案分别治疗晚期NSLC的临床效果，探讨参芪扶正联合GP方案对于晚期NSLC治疗效果。方法回顾性分析2010年9月～2013年9月间我院收治的60例晚期非小细胞肺癌（NSCLC）患者为研究对象，其中采用参芪扶正联合GP方案化疗者30例(治疗组)，单独采用GP方案化疗者30例（对照组）分析比较两组患者的近期临床疗效及其对患者生活质量的影响。结果治疗组客观有效率为53.3%，对照组有效率为26.7%，治疗组显著高于对照组（x2=4.4，P=0.03＜0.05）；治疗组生活质量提高者比例为50%显著多于对照组16.7%，且差别有统计学意义（x2=7.5，P=0.006＜0.05）；治疗组治疗期间发生白细胞下降4例，胃肠道反应7例，血小板下降6例；对照组发生白细胞下降12例，胃肠道反应6例，血小板下降7例。治疗组白细胞下降发生率显著低于对照组（x2=5.6，P=0.02＜0.05）。结论参芪扶正联合GP方案治疗晚期NSCLC可显著提高临床疗效，降低白细胞下降不良反应发生风险。
目的：通過對比參芪扶正聯閤GP方案與GP方案分彆治療晚期NSLC的臨床效果，探討參芪扶正聯閤GP方案對于晚期NSLC治療效果。方法迴顧性分析2010年9月～2013年9月間我院收治的60例晚期非小細胞肺癌（NSCLC）患者為研究對象，其中採用參芪扶正聯閤GP方案化療者30例(治療組)，單獨採用GP方案化療者30例（對照組）分析比較兩組患者的近期臨床療效及其對患者生活質量的影響。結果治療組客觀有效率為53.3%，對照組有效率為26.7%，治療組顯著高于對照組（x2=4.4，P=0.03＜0.05）；治療組生活質量提高者比例為50%顯著多于對照組16.7%，且差彆有統計學意義（x2=7.5，P=0.006＜0.05）；治療組治療期間髮生白細胞下降4例，胃腸道反應7例，血小闆下降6例；對照組髮生白細胞下降12例，胃腸道反應6例，血小闆下降7例。治療組白細胞下降髮生率顯著低于對照組（x2=5.6，P=0.02＜0.05）。結論參芪扶正聯閤GP方案治療晚期NSCLC可顯著提高臨床療效，降低白細胞下降不良反應髮生風險。
목적：통과대비삼기부정연합GP방안여GP방안분별치료만기NSLC적림상효과，탐토삼기부정연합GP방안대우만기NSLC치료효과。방법회고성분석2010년9월～2013년9월간아원수치적60례만기비소세포폐암（NSCLC）환자위연구대상，기중채용삼기부정연합GP방안화료자30례(치료조)，단독채용GP방안화료자30례（대조조）분석비교량조환자적근기림상료효급기대환자생활질량적영향。결과치료조객관유효솔위53.3%，대조조유효솔위26.7%，치료조현저고우대조조（x2=4.4，P=0.03＜0.05）；치료조생활질량제고자비례위50%현저다우대조조16.7%，차차별유통계학의의（x2=7.5，P=0.006＜0.05）；치료조치료기간발생백세포하강4례，위장도반응7례，혈소판하강6례；대조조발생백세포하강12례，위장도반응6례，혈소판하강7례。치료조백세포하강발생솔현저저우대조조（x2=5.6，P=0.02＜0.05）。결론삼기부정연합GP방안치료만기NSCLC가현저제고림상료효，강저백세포하강불량반응발생풍험。
Objective The aim of this study was to evaluate the clinical efficacy of shenqifuzheng combined with GP regimen in the treatment of non-small cell lung carcinoma. Methods 60 cases with NSCLC was retrospectively analyzed in our hospital from 2010 to 2013.Of the included 60 cases,30 patients were treated with GP+Shenqifuzheng and other 30 cases were treated with GP chemotherapy only.The clinical efficacy,life quality improvement and side effects were compared between the two groups. Results The objective response rate was 53.3% and 26.7% in the treatment and control group respectively,with statistical difference between the two groups(x2=4.44,P=0.03<0.05);The life quality improvement in the treatment was much higher than that of control group(x2=7.5,P=0.006 < 0.05);The granulocytopenia risk in treatment group was much lower than that of control group(x2=5.6,P=0.02 < 0.05). Conclusion Shenqifuzheng combined with GP regimen chemotherapy can significant improve the clinical efficacy and decrease the risk of side effects in patients with non-small cell lung cancer.
